Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 23, 2016 ) Publisher's "Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023" report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). The report also includes global market size of the Graft Versus Host Disease (GVHD) for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). Publisher forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to Publisher's estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.92%, 2.73% and 2.71% for U.S., EU5 and Japan, respectively, from 2013 to 2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). For the United States, as per Publisher forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 1.00% and 4.14%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 1.00% and 4.14%, respectively, by the end of the year 2023.
For more information about this report: http://www.reportsweb.com/graft-versus-host-disease-gvhd-market-insights-epidemiology-and-market-forecast-2023
The market size of GVHD mainly comprises of the off-label biologics. Many companies are working on the development of targeted therapy and in the near future, these drugs may create an impact on the overall market size of GVHD. Publisher's estimates suggest that the global forecasted market size of Graft Versus Host Disease (GVHD) shall increase at a CAGR of 5.47% from 2013 to 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts. Scope - Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options. - It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants (HSCTs) ( which also includes the cases of first transplants along with the total transplants) - The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors (Sibling donors and unrelated donors) for 7MM from 2013-2023. - The Report also includes historical and forecasted Market size of GVHD for 7MM from 2013 to 2023. - It provides the information of available marketed therapies, including off-label biologics, patent and exclusivity details. - The report also focuses on the details of pipeline drugs in the pivotal stage of development including their SWOT Analysis and expected launch date, which shall help to predict the impact of those drugs on the market size in the near future.
Table Of Content:- Graft Versus Host Disease (GVHD) Disease Definition Disease Types Acute GvHD Chronic GvHD Grades of GvHD Pathophysiology Risk Factors for GVHD Diagnosis Epidemiology and Patient Population Key Points: UNITED STATES Assumptions and Rationale Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States EUROPE Assumptions and Rationale Germany Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany France Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France Spain Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain Italy Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy United Kingdom Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK JAPAN Assumptions and Rationale Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan Treatment Algorithm Guidelines and Recommendations for Treatment of GvHD
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001426088/sample
Europe Japan United States Current Unmet Needs of Graft Versus Host Disease (GVHD) Marketed Drugs Temcell HS Regulatory Milestones Advantages & Disadvantages Product Profile Safety and Efficacy of Temcell HS Side effects of Temcell HS SWOT Analysis of Temcell HS Remicade Regulatory Milestones Advantages & Disadvantages Product Profile Safety and Efficacy of Remicade Side effects of Remicade SWOT Analysis Lemtrada Regulatory Milestones Advantages & Disadvantages Product Profile Safety and Efficacy of Lemtrada Adverse reactions of Lemtrada SWOT Analysis Velcade Regulatory Milestones Advantages & Disadvantages Product Profile Safety and Efficacy of Velcade Side effects of Velcade SWOT Analysis Gleevec Regulatory Milestones Advantages & Disadvantages Product Profile Safety and Efficacy of Gleevec Adverse reactions of Gleevec SWOT Analysis Rapamune Regulatory Milestones Advantages & Disadvantages Product Profile Safety and Efficacy of Rapamune Adverse reactions of Rapamune SWOT Analysis Simulect Regulatory Milestones Advantages and Disadvantages Product Profile Safety and Efficacy of Simulect Side effects of Simulect SWOT Analysis Enbrel Regulatory Milestones Advantages and Disadvantages Product Profile Safety and Efficacy of Enbrel Side effects of Enbrel SWOT Analysis Orencia Regulatory Milestones Advantages and Disadvantages Product Profile Safety and Efficacy of Orencia Side effects of Orencia SWOT Analysis Nulojix Regulatory Milestones Advantages and Disadvantages Product Profile Safety and Efficacy of Nulojix Side effects of Orencia SWOT Analysis Emerging Drugs Analysis Emerging Drugs Begelomab Regulatory Milestones Clinical Development Product Profile Clinical Pipeline Activity Ongoing Trials Information Clinical Trial by Phase SWOT Analysis Budesonide Regulatory Milestones Clinical Development Product Profile Clinical Pipeline Activity Ongoing Trials Information Clinical Trial by Phase SWOT Analysis Methoxsalen Regulatory Milestones Clinical Development Product Profile Clinical Pipeline Activity Ongoing Trials Information Clinical Trial by Phase SWOT Analysis Market Size Global Market Size of GVHD Total Market Size of GVHD Region-Wise Market size of GVHD UNITED STATES Total Market Size of GVHD Market Size of GVHD by Treatment Type EUROPE Spain Total Market Size of GVHD Market Size of GVHD by Treatment Type United Kingdom Total Market Size of GVHD Market Size of GVHD by Treatment Type France Total Market Size of GVHD Market Size of GVHD by Treatment Type Italy Total Market Size of GVHD Market Size of GVHD by Treatment Type Germany Total Market Size of GVHD Market Size of GVHD by Treatment Type JAPAN Total Market Size of GVHD Market Size of GVHD by Treatment Type Market Drivers Market Barriers Appendix Report Methodology Consulting Services Disclaimer About DelveInsight
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001426088/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|